CTF Young Investigator Award
CTF’s longest running program, YIA provides two-year awards for young scientists early in their careers, bringing them into the NF field and helping to establish them as independent investigators. Implemented over 30 years ago by the Foundation, the YIA program was until 2006 CTF’s sole ongoing grant mechanism. Click here for Applicant Eligibility Guidelines.
Though a number of YIAs have made significant research findings and made notable publications the main function of the YIA program has been as a ‘seeding mechanism’ for researchers who went on to secure larger grants from NIH and CDMRP NFRP. CTF’s “seeding” of the NF field with new talent has been hailed as a key reason why NF research has grown rapidly in the past 25+ years. Between 2005 and 2008 the YIA program doubled in size from 5 to 10 funded awards (8 postdoctoral and 2 predoctoral). In the same period number of applications submitted increased from 16 (2005) to 34 (2008). The success rate of this program remains extraordinarily high at around 30%. CTF funded 11 YIAs in 2012 and 9 YIAs in 2013 with grants ranging from $64,000 to $108,000 each.
Founded in 1978, the Children's Tumor Foundation is a non-profit organization committed to identifying effective drug therapies for neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2) and Schwannomatosis, and to improving the lives of those living with these disorders. There is currently no effective drug treatment for any of these disorders (collectively called NF), which affect an estimated 100,000 persons in the US. Since its inception, the Children’s Tumor Foundation has committed over $30 million to research grants and initiatives, supporting scientists around the world to conduct groundbreaking NF research.
We MUST RECEIVE completed Pre-Applications by 5:00 p.m. ET
January 27, 2014
Pre-Applications received after this date will NOT be reviewed.
Following review, invitation letters for Full Applications will be issued by
February 3, 2014
Click here for Applicant Eligibility Guidelines
Full Applications will be due on
March 4, 2014
(Please Note: The dates above are correct. Please ignore the due dates within the Pre-Application document)
2013 POSTDOCTORAL AWARDEES
Lu Zhou, Peninsula School of Medicine and Dentistry, UK
KSR1 as a Potential Therapeutic Target for Both NF1 and NF2
NF1 patients can develop plexiform neurofibromas (benign tumors that grow along nerves) which can become malignant peripheral nerve sheath tumors (MPNST) in 10% of cases. NF2 patients are likely to develop tumors of the Schwann cells called schwannomas, which lead to significant medical problems. Currently, there is no approved drug therapy for these complications of NF1 and NF2. This project will use cell cultures to explore the tumor-suppressing activity of Kinase Suppressor of Ras 1 (KSR1) as a new approach for the treatment of both NF1 and NF2.